← All stories
● Covered by 1 source · 1 reportMedium impact1 neutral

Science Corporation Raises $400M Series D, Valuing Brain Tech Startup at $3.5B

🔄 Updated 4d ago
New to BrevFeed? We gather this story from every outlet covering it into one summary — ranked by real-world impact, not just the latest headline — so you never miss what matters. What is BrevFeed? →

Key points

  • Science Corporation raised $400 million in Series D funding.
  • The new funding round values the company at $3.5 billion.
  • Funds will support U.S. FDA approval for the PRIMA vision device.
  • Company is developing a bio-hybrid brain sensor for neurological conditions.

New Funding Round and Valuation

Science Corporation, founded by former Neuralink president Max Hodak, announced it has raised $400 million in a Series D funding round. This investment values the medical technology startup at $3.5 billion. Key investors in this round include Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator, and PLC Neurotech.

PRIMA Device Expansion

The company's initial product, PRIMA, is a wearable and implantable chip designed to help individuals with age-related macular degeneration recover vision. PRIMA is currently approved in Europe and available in Germany. Science Corporation is also trialing PRIMA for Stargardt disease, another cause of blindness. The new funding will facilitate the device's entry into the United States via the FDA’s Humanitarian Device Exemption, which allows experimental medical technology for rare conditions.

Advancing Brain-Computer Interface Technology

Beyond PRIMA, Science Corporation's long-term goal is to establish direct connections with the human brain using a bio-hybrid sensor. This sensor combines cultured neurons with silicon components. The company is currently designing initial human trials for this device in collaboration with Yale neurosurgery professor Murat Günel, with potential applications for conditions like Parkinson’s disease and other brain injuries.

Impact on Medical Technology

The substantial funding and valuation underscore investor confidence in Science Corporation's approach to neurotechnology. The expansion of PRIMA into the U.S. market could offer new treatment options for specific vision impairments, while the development of its bio-hybrid brain sensor represents a step toward advanced treatments for neurological disorders.

✨ This summary was generated by AI from the outlets' reporting listed below. It is not independently verified and may contain errors — check the original sources. How BrevFeed works →

The daily brief

One email each morning: the day's tech stories, clustered across outlets and summarized. No account needed.

One email a day. Unsubscribe in one click, any time.

Today's brief

Spend a few minutes, get the whole day. Every topic's top stories in one hands-free rundown — listen, watch, or read the transcript.

~4 min · 3 stories · Nov 21

▶ Play today's brief Listen on Spotify

New every morning, and the back catalogue is archived by date.

Reporting from

Science Corporation, a medical technology startup, secured $400 million in Series D funding, bringing its valuation to $3.5 billion. This funding will support the company's efforts to bring its PRIMA vision-restoration device to the U.S. market and advance its bio-hybrid brain sensor technology.